サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1285898

RAS作動薬市場：薬剤クラス別（ACE阻害薬、ARB、レニン阻害薬、アルドステロン拮抗薬、その他）- 世界の産業分析、規模、シェア、成長、動向、予測、2023-2031年

RAS-acting Agents Market (Drug Class: ACE Inhibitors, Angiotensin II Receptor Blockers [ARBs], Renin Inhibitors, Aldosterone Antagonists, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
出版日: | 発行: Transparency Market Research | ページ情報: 英文 209 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=149.62円
RAS作動薬市場：薬剤クラス別（ACE阻害薬、ARB、レニン阻害薬、アルドステロン拮抗薬、その他）- 世界の産業分析、規模、シェア、成長、動向、予測、2023-2031年
出版日: 2023年04月30日
発行: Transparency Market Research
ページ情報: 英文 209 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

RAS作動薬市場- 調査範囲

TMRの「RAS作動薬の世界市場」レポートは、2023年から2031年までの予測期間における市場の指標について貴重な洞察を得るために、過去だけでなく現在の成長動向と機会も調査しています。本レポートでは、2023年を基準年、2031年を予測年として、2017年から2031年までの期間における世界のRAS作動薬市場の収益を提供します。また、2023年から2031年までの世界のRAS作動薬市場の複合年間成長率（CAGR %）を掲載しています。

本レポートは、広範な調査を経て作成されました。1次調査では、アナリストが主要オピニオンリーダー、業界リーダー、オピニオンメーカーへのインタビューを実施し、調査作業の大部分を行っています。2次調査では、主要企業の製品資料、年次報告書、プレスリリース、関連文書などを参照し、RAS作動薬市場を把握しました。

本レポートは、世界のRAS作動薬市場の競合情勢を掘り下げています。世界のRAS作動薬市場で活動する主要企業が特定され、それぞれの企業が様々な属性でプロファイリングされています。企業概要、財務状況、最近の動向、SWOTは、本レポートで紹介されている世界のRAS作動薬市場におけるプレイヤーの属性です。

目次

第1章 序文

  • 市場の定義とスコープ
  • 市場セグメンテーション
  • 主な調査目的
  • 調査ハイライト

第2章 前提条件と調査手法

第3章 エグゼクティブサマリー：世界市場

第4章 市場の概要

  • イントロダクション
    • セグメントの定義
    • 業界の進化/発展
  • 概要
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
  • 世界市場の分析・予測、2017年～2031年

第5章 主要洞察

  • 技術的進歩
  • 世界の主要国での疾患有病率・発症率
  • 主要な業界イベント
  • COVID-19の影響分析

第6章 世界市場分析・予測：薬剤クラス別

  • イントロダクションと定義
  • 主な調査結果/発展状況
  • 市場価値予測：薬剤クラス別、2017-2031年
    • ACE阻害薬
    • アンジオテンシンII受容体拮抗薬（ARB）
    • レニン阻害薬
    • アルドステロン拮抗薬
    • その他（利尿剤）
  • 市場魅力度分析：薬剤クラス別

第7章 世界市場分析・予測：適応症別

  • イントロダクションと定義
  • 主な調査結果/発展状況
  • 市場価値予測：適応症別、2017年～2031年
    • 高血圧症
    • 心不全
    • 慢性腎臓病
    • 糖尿病性腎症
    • 冠動脈疾患
  • 市場魅力度分析：適応症別

第8章 世界市場分析・予測：流通チャネル別

  • イントロダクションと定義
  • 主な調査結果/発展状況
  • 市場価値予測：流通チャネル別、2017年～2031年
    • 病院薬局
    • 小売薬局
    • オンライン薬局
  • 市場魅力度分析：流通チャネル別

第9章 世界市場分析・予測：地域別

  • 主な調査結果
  • 市場規模予測：地域別、2017-2031年
    • 北米
    • 欧州
    • アジア太平洋
    • ラテンアメリカ
    • 中東・アフリカ地域
  • 市場魅力度分析：地域別

第10章 北米市場の分析・予測

  • イントロダクション
    • 主な調査結果
  • 市場価値予測：薬剤クラス別、2017-2031年
    • ACE阻害薬
    • アンジオテンシンII受容体遮断薬（ARB）
    • レニン阻害薬
    • アルドステロン拮抗薬
    • その他（利尿剤）
  • 市場価値予測：適応症別、2017-2031年
    • 高血圧症
    • 心不全
    • 慢性腎臓病
    • 糖尿病性腎症
    • 冠動脈疾患
  • 市場価値予測：流通チャネル別、2017-2031年
    • 病院薬局
    • 小売薬局
    • オンライン薬局
  • 市場価値予測：国別、2017-2031年
    • 米国
    • カナダ
  • 市場魅力度分析
    • 薬剤クラス別
    • 適応症別
    • 販売チャネル別
    • 国別

第11章 欧州市場の分析・予測

  • イントロダクション
    • 主要な調査結果
  • 市場価値予測：薬剤クラス別、2017-2031年
    • ACE阻害薬
    • アンジオテンシンII受容体拮抗薬（ARB）
    • レニン阻害薬
    • アルドステロン拮抗薬
    • その他（利尿剤）
  • 市場価値予測：適応症別、2017-2031年
    • 高血圧症
    • 心不全
    • 慢性腎臓病
    • 糖尿病性腎症
    • 冠動脈疾患
  • 市場価値予測：流通チャネル別、2017-2031年
    • 病院薬局
    • 小売薬局
    • オンライン薬局
  • 市場価値予測：国/サブリージョン別、2017-2031年
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 市場魅力度分析
    • 薬剤クラス別
    • 適応症別
    • 販売チャネル別
    • 国/サブリージョン別

第12章 アジア太平洋地域の市場分析・予測

  • イントロダクション
    • 主な調査結果
  • 市場価値予測：薬剤クラス別、2017-2031年
    • ACE阻害薬
    • アンジオテンシンII受容体遮断薬（ARB）
    • レニン阻害薬
    • アルドステロン拮抗薬
    • その他（利尿剤）
  • 市場価値予測：適応症別、2017-2031年
    • 高血圧症
    • 心不全
    • 慢性腎臓病
    • 糖尿病性腎症
    • 冠動脈疾患
  • 市場価値予測：流通チャネル別、2017-2031年
    • 病院薬局
    • 小売薬局
    • オンライン薬局
  • 市場価値予測：国/サブリージョン別、2017-2031年
    • 中国
    • 日本
    • インド
    • オーストラリア・ニュージーランド
    • その他アジア太平洋地域
  • 市場魅力度分析
    • 薬剤クラス別
    • 適応症別
    • 販売チャネル別
    • 国/サブリージョン別

第13章 ラテンアメリカ（LATAM）市場の分析・予測

  • イントロダクション
    • 主要な調査結果
  • 市場価値予測：薬剤クラス別、2017年～2031年
    • ACE阻害薬
    • アンジオテンシンII受容体遮断薬（ARB）
    • レニン阻害薬
    • アルドステロン拮抗薬
    • その他（利尿剤）
  • 市場価値予測：適応症別、2017-2031年
    • 高血圧症
    • 心不全
    • 慢性腎臓病
    • 糖尿病性腎症
    • 冠動脈疾患
  • 市場価値予測：流通チャネル別、2017-2031年
    • 病院薬局
    • 小売薬局
    • オンライン薬局
  • 市場価値予測：国/サブリージョン別、2017-2031年
    • ブラジル
    • メキシコ
    • その他のLATAM地域
  • 市場魅力度分析
    • 薬剤クラス別
    • 適応症別
    • 販売チャネル別
    • 国/サブリージョン別

第14章 中東・アフリカ市場の分析・予測

  • イントロダクション
    • 主な調査結果
  • 市場価値予測：薬剤クラス別、2017-2031年
    • ACE阻害薬
    • アンジオテンシンII受容体遮断薬（ARB）
    • レニン阻害薬
    • アルドステロン拮抗薬
    • その他（利尿剤）
  • 市場価値予測：適応症別、2017-2031年
    • 高血圧症
    • 心不全
    • 慢性腎臓病
    • 糖尿病性腎症
    • 冠動脈疾患
  • 市場価値予測：流通チャネル別、2017-2031年
    • 病院薬局
    • 小売薬局
    • オンライン薬局
  • 市場価値予測：国/サブリージョン別、2017-2031年
    • GCC諸国
    • 南アフリカ
    • その他中東・アフリカ
  • 市場魅力度分析
    • 薬剤クラス別
    • 適応症別
    • 販売チャネル別
    • 国/サブリージョン別

第15章 競合情勢

  • 市場プレイヤー-競争マトリックス（企業階層別、企業規模別）
  • 市場シェア分析：企業別（2022年版）
  • 企業プロファイル
    • Novartis AG
    • Pfizer, Inc.
    • AstraZeneca plc
    • Merck & Co., Inc.
    • Sanofi S.A.
    • Bristol-Myers Squibb Company
    • Daiichi Sankyo Company, Limited
    • Takeda Pharmaceutical Company Limited
    • Boehringer Ingelheim GmbH
    • Johnson & Johnson
図表

List of Tables

  • Table 01: Global RAS-acting Agents Market Size (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 02: Global RAS-acting Agents Market Size (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 03: Global RAS-acting Agents Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 04: Global RAS-acting Agents Market Size (US$ Mn) Forecast, by Region, 2017-2031
  • Table 05: North America RAS-acting Agents Market Size (US$ Mn) Forecast, by Country, 2017-2031
  • Table 06: North America RAS-acting Agents Market Size (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 07: North America RAS-acting Agents Market Size (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 08: North America RAS-acting Agents Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 09: Europe RAS-acting Agents Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 10: Europe RAS-acting Agents Market Size (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 11: Europe RAS-acting Agents Market Size (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 12: Europe RAS-acting Agents Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 13: Asia Pacific RAS-acting Agents Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 14: Asia Pacific RAS-acting Agents Market Size (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 15: Asia Pacific RAS-acting Agents Market Size (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 16: Asia Pacific RAS-acting Agents Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 17: Latin America RAS-acting Agents Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 18: Latin America RAS-acting Agents Market Size (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 19: Latin America RAS-acting Agents Market Size (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 20: Latin America RAS-acting Agents Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 21: Middle East & Africa RAS-acting Agents Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 22: Middle East & Africa RAS-acting Agents Market Size (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 23: Middle East & Africa RAS-acting Agents Market Size (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 24: Middle East & Africa RAS-acting Agents Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031

List of Figures

  • Figure 01: Global RAS-acting Agents Market Size (US$ Mn) and Distribution (%), by Region, 2022 and 2031
  • Figure 02: Global RAS-acting Agents Market Revenue (US$ Mn), by Drug Class, 2022
  • Figure 03: Global RAS-acting Agents Market Value Share, by Drug Class, 2022
  • Figure 04: Global RAS-acting Agents Market Revenue (US$ Mn), by Indication, 2022
  • Figure 05: Global RAS-acting Agents Market Value Share, by Indication, 2022
  • Figure 06: Global RAS-acting Agents Market Revenue (US$ Mn), by Distribution Channel, 2022
  • Figure 07: Global RAS-acting Agents Market Value Share, by Distribution Channel, 2022
  • Figure 08: Global RAS-acting Agents Market Value Share, by Region, 2022
  • Figure 09: Global RAS-acting Agents Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 10: Global RAS-acting Agents Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 11: Global RAS-acting Agents Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 12: Global RAS-acting Agents Market Value Share Analysis, by Indication, 2022 and 2031
  • Figure 13: Global RAS-acting Agents Market Attractiveness Analysis, by Indication, 2023-2031
  • Figure 14: Global RAS-acting Agents Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 15: Global RAS-acting Agents Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 16: Global RAS-acting Agents Market Value Share Analysis, by Region, 2022 and 2031
  • Figure 17: Global RAS-acting Agents Market Attractiveness Analysis, by Region, 2023-2031
  • Figure 18: North America RAS-acting Agents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 19: North America RAS-acting Agents Market Attractiveness Analysis, by Country, 2017-2031
  • Figure 20: North America RAS-acting Agents Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 21: North America RAS-acting Agents Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 22: North America RAS-acting Agents Market Value Share Analysis, by Indication, 2022 and 2031
  • Figure 23: North America RAS-acting Agents Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 24: North America RAS-acting Agents Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 25: North America RAS-acting Agents Market Attractiveness Analysis, by Indication, 2023-2031
  • Figure 26: North America RAS-acting Agents Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 27: Europe RAS-acting Agents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 28: Europe RAS-acting Agents Market Attractiveness Analysis, by Country/Sub-region, 2017-2031
  • Figure 29: Europe RAS-acting Agents Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 30: Europe RAS-acting Agents Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 31: Europe RAS-acting Agents Market Value Share Analysis, by Indication, 2022 and 2031
  • Figure 32: Europe RAS-acting Agents Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 33: Europe RAS-acting Agents Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 34: Europe RAS-acting Agents Market Attractiveness Analysis, by Indication, 2023-2031
  • Figure 35: Europe RAS-acting Agents Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 36: Asia Pacific RAS-acting Agents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 37: Asia Pacific RAS-acting Agents Market Attractiveness Analysis, by Country/Sub-region, 2017-2031
  • Figure 38: Asia Pacific RAS-acting Agents Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 39: Asia Pacific RAS-acting Agents Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 40: Asia Pacific RAS-acting Agents Market Value Share Analysis, by Indication, 2022 and 2031
  • Figure 41: Asia Pacific RAS-acting Agents Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 42: Asia Pacific RAS-acting Agents Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 43: Asia Pacific RAS-acting Agents Market Attractiveness Analysis, by Indication, 2023-2031
  • Figure 44: Asia Pacific RAS-acting Agents Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 45: Latin America RAS-acting Agents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 46: Latin America RAS-acting Agents Market Attractiveness Analysis, by Country/Sub-region, 2017-2031
  • Figure 47: Latin America RAS-acting Agents Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 48: Latin America RAS-acting Agents Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 49: Latin America RAS-acting Agents Market Value Share Analysis, by Indication, 2022 and 2031
  • Figure 50: Latin America RAS-acting Agents Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 51: Latin America RAS-acting Agents Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 52: Latin America RAS-acting Agents Market Attractiveness Analysis, by Indication, 2023-2031
  • Figure 53: Latin America RAS-acting Agents Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 54: Middle East & Africa RAS-acting Agents Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 55: Middle East & Africa RAS-acting Agents Market Attractiveness Analysis, by Country/Sub-region, 2017-2031
  • Figure 56: Middle East & Africa RAS-acting Agents Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 57: Middle East & Africa RAS-acting Agents Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 58: Middle East & Africa RAS-acting Agents Market Value Share Analysis, by Indication, 2022 and 2031
  • Figure 59: Middle East & Africa RAS-acting Agents Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 60: Middle East & Africa RAS-acting Agents Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 61: Middle East & Africa RAS-acting Agents Market Attractiveness Analysis, by Indication, 2023-2031
  • Figure 62: Middle East & Africa RAS-acting Agents Market Attractiveness Analysis, by Distribution Channel, 2023-2031
目次
Product Code: TMRGL85539

RAS-acting Agents Market - Scope of Report

TMR's report on the global RAS-acting Agents Market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global RAS-acting Agents Market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global RAS-acting Agents Market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the RAS-acting Agents market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global RAS-acting Agents market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global RAS-acting Agents market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global RAS-acting Agents market.

The report delves into the competitive landscape of the global RAS-acting Agents market. Key players operating in the global RAS-acting Agents Market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global RAS-acting Agents Market profiled in this report.

Key Questions Answered in Global RAS-acting Agents Market Report:

  • What is the sales/revenue generated by RAS-acting Agents across all regions during the forecast period?
  • What are the opportunities in the global RAS-acting Agents market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

RAS-acting Agents Market - Research Objectives and Research Approach

The comprehensive report on the global RAS-acting Agents Market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global RAS-acting Agents Market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global RAS-acting Agents market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global RAS-acting Agents Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Segment Definition
    • 4.1.2. Industry Evolution/Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global RAS-acting Agents Market Analysis and Forecast, 2017-2031

5. Key Insights

  • 5.1. Technological Advancements
  • 5.2. Disease Prevalence & Incidence Rate Globally With Key Countries
  • 5.3. Key Industry Events
  • 5.4. COVID-19 Impact Analysis

6. Global RAS-acting Agents Market Analysis and Forecast, by Drug Class

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Drug Class, 2017-2031
    • 6.3.1. ACE inhibitors
    • 6.3.2. Angiotensin II Receptor Blockers (ARBs)
    • 6.3.3. Renin Inhibitors
    • 6.3.4. Aldosterone Antagonists
    • 6.3.5. Others (diuretics)
  • 6.4. Market Attractiveness Analysis, by Drug Class

7. Global RAS-acting Agents Market Analysis and Forecast, by Indication

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Indication, 2017-2031
    • 7.3.1. Hypertension
    • 7.3.2. Heart Failure
    • 7.3.3. Chronic Kidney Disease
    • 7.3.4. Diabetic Nephropathy
    • 7.3.5. Coronary Artery Disease
  • 7.4. Market Attractiveness Analysis, by Indication

8. Global RAS-acting Agents Market Analysis and Forecast, by Distribution Channel

  • 8.1. Introduction & Definition
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Retail Pharmacies
    • 8.3.3. Online Pharmacies
  • 8.4. Market Attractiveness Analysis, by Distribution Channel

9. Global RAS-acting Agents Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, by Region, 2017-2031
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness Analysis, by Region

10. North America RAS-acting Agents Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, by Drug Class, 2017-2031
    • 10.2.1. ACE inhibitors
    • 10.2.2. Angiotensin II Receptor Blockers (ARBs)
    • 10.2.3. Renin Inhibitors
    • 10.2.4. Aldosterone Antagonists
    • 10.2.5. Others (diuretics)
  • 10.3. Market Value Forecast, by Indication, 2017-2031
    • 10.3.1. Hypertension
    • 10.3.2. Heart Failure
    • 10.3.3. Chronic Kidney Disease
    • 10.3.4. Diabetic Nephropathy
    • 10.3.5. Coronary Artery Disease
  • 10.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 10.4.1. Hospital Pharmacies
    • 10.4.2. Retail Pharmacies
    • 10.4.3. Online Pharmacies
  • 10.5. Market Value Forecast, by Country, 2017-2031
    • 10.5.1. U.S.
    • 10.5.2. Canada
  • 10.6. Market Attractiveness Analysis
    • 10.6.1. By Drug Class
    • 10.6.2. By Indication
    • 10.6.3. By Distribution Channel
    • 10.6.4. By Country

11. Europe RAS-acting Agents Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Drug Class, 2017-2031
    • 11.2.1. ACE inhibitors
    • 11.2.2. Angiotensin II Receptor Blockers (ARBs)
    • 11.2.3. Renin Inhibitors
    • 11.2.4. Aldosterone Antagonists
    • 11.2.5. Others (diuretics)
  • 11.3. Market Value Forecast, by Indication, 2017-2031
    • 11.3.1. Hypertension
    • 11.3.2. Heart Failure
    • 11.3.3. Chronic Kidney Disease
    • 11.3.4. Diabetic Nephropathy
    • 11.3.5. Coronary Artery Disease
  • 11.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 11.4.1. Hospital Pharmacies
    • 11.4.2. Retail Pharmacies
    • 11.4.3. Online Pharmacies
  • 11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 11.5.1. Germany
    • 11.5.2. U.K.
    • 11.5.3. France
    • 11.5.4. Italy
    • 11.5.5. Spain
    • 11.5.6. Rest of Europe
  • 11.6. Market Attractiveness Analysis
    • 11.6.1. By Drug Class
    • 11.6.2. By Indication
    • 11.6.3. By Distribution Channel
    • 11.6.4. By Country/Sub-region

12. Asia Pacific RAS-acting Agents Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Drug Class, 2017-2031
    • 12.2.1. ACE inhibitors
    • 12.2.2. Angiotensin II Receptor Blockers (ARBs)
    • 12.2.3. Renin Inhibitors
    • 12.2.4. Aldosterone Antagonists
    • 12.2.5. Others (diuretics)
  • 12.3. Market Value Forecast, by Indication, 2017-2031
    • 12.3.1. Hypertension
    • 12.3.2. Heart Failure
    • 12.3.3. Chronic Kidney Disease
    • 12.3.4. Diabetic Nephropathy
    • 12.3.5. Coronary Artery Disease
  • 12.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 12.4.1. Hospital Pharmacies
    • 12.4.2. Retail Pharmacies
    • 12.4.3. Online Pharmacies
  • 12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.5.1. China
    • 12.5.2. Japan
    • 12.5.3. India
    • 12.5.4. Australia & New Zealand
    • 12.5.5. Rest of Asia Pacific
  • 12.6. Market Attractiveness Analysis
    • 12.6.1. By Drug Class
    • 12.6.2. By Indication
    • 12.6.3. By Distribution Channel
    • 12.6.4. By Country/Sub-region

13. Latin America (LATAM) RAS-acting Agents Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Drug Class, 2017-2031
    • 13.2.1. ACE inhibitors
    • 13.2.2. Angiotensin II Receptor Blockers (ARBs)
    • 13.2.3. Renin Inhibitors
    • 13.2.4. Aldosterone Antagonists
    • 13.2.5. Others (diuretics)
  • 13.3. Market Value Forecast, by Indication, 2017-2031
    • 13.3.1. Hypertension
    • 13.3.2. Heart Failure
    • 13.3.3. Chronic Kidney Disease
    • 13.3.4. Diabetic Nephropathy
    • 13.3.5. Coronary Artery Disease
  • 13.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 13.4.1. Hospital Pharmacies
    • 13.4.2. Retail Pharmacies
    • 13.4.3. Online Pharmacies
  • 13.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.5.1. Brazil
    • 13.5.2. Mexico
    • 13.5.3. Rest of LATAM
  • 13.6. Market Attractiveness Analysis
    • 13.6.1. By Drug Class
    • 13.6.2. By Indication
    • 13.6.3. By Distribution Channel
    • 13.6.4. By Country/Sub-region

14. Middle East & Africa RAS-acting Agents Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Drug Class, 2017-2031
    • 14.2.1. ACE inhibitors
    • 14.2.2. Angiotensin II Receptor Blockers (ARBs)
    • 14.2.3. Renin Inhibitors
    • 14.2.4. Aldosterone Antagonists
    • 14.2.5. Others (diuretics)
  • 14.3. Market Value Forecast, by Indication, 2017-2031
    • 14.3.1. Hypertension
    • 14.3.2. Heart Failure
    • 14.3.3. Chronic Kidney Disease
    • 14.3.4. Diabetic Nephropathy
    • 14.3.5. Coronary Artery Disease
  • 14.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 14.4.1. Hospital Pharmacies
    • 14.4.2. Retail Pharmacies
    • 14.4.3. Online Pharmacies
  • 14.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.5.1. GCC Countries
    • 14.5.2. South Africa
    • 14.5.3. Rest of Middle East & Africa
  • 14.6. Market Attractiveness Analysis
    • 14.6.1. By Drug Class
    • 14.6.2. By Indication
    • 14.6.3. By Distribution Channel
    • 14.6.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competitive Matrix (by tier and size of companies)
  • 15.2. Market Share Analysis, by Company (2022)
  • 15.3. Company Profiles
    • 15.3.1. Novartis AG
      • 15.3.1.1. Company Overview
      • 15.3.1.2. Drug Class Portfolio
      • 15.3.1.3. SWOT Analysis
      • 15.3.1.4. Financial Overview
      • 15.3.1.5. Strategic Overview
    • 15.3.2. Pfizer, Inc.
      • 15.3.2.1. Company Overview
      • 15.3.2.2. Drug Class Portfolio
      • 15.3.2.3. SWOT Analysis
      • 15.3.2.4. Financial Overview
      • 15.3.2.5. Strategic Overview
    • 15.3.3. AstraZeneca plc
      • 15.3.3.1. Company Overview
      • 15.3.3.2. Drug Class Portfolio
      • 15.3.3.3. SWOT Analysis
      • 15.3.3.4. Financial Overview
      • 15.3.3.5. Strategic Overview
    • 15.3.4. Merck & Co., Inc.
      • 15.3.4.1. Company Overview
      • 15.3.4.2. Drug Class Portfolio
      • 15.3.4.3. SWOT Analysis
      • 15.3.4.4. Financial Overview
      • 15.3.4.5. Strategic Overview
    • 15.3.5. Sanofi S.A.
      • 15.3.5.1. Company Overview
      • 15.3.5.2. Drug Class Portfolio
      • 15.3.5.3. SWOT Analysis
      • 15.3.5.4. Financial Overview
      • 15.3.5.5. Strategic Overview
    • 15.3.6. Bristol-Myers Squibb Company
      • 15.3.6.1. Company Overview
      • 15.3.6.2. Drug Class Portfolio
      • 15.3.6.3. SWOT Analysis
      • 15.3.6.4. Financial Overview
      • 15.3.6.5. Strategic Overview
    • 15.3.7. Daiichi Sankyo Company, Limited
      • 15.3.7.1. Company Overview
      • 15.3.7.2. Drug Class Portfolio
      • 15.3.7.3. SWOT Analysis
      • 15.3.7.4. Financial Overview
      • 15.3.7.5. Strategic Overview
    • 15.3.8. Takeda Pharmaceutical Company Limited
      • 15.3.8.1. Company Overview
      • 15.3.8.2. Drug Class Portfolio
      • 15.3.8.3. SWOT Analysis
      • 15.3.8.4. Financial Overview
      • 15.3.8.5. Strategic Overview
    • 15.3.9. Boehringer Ingelheim GmbH
      • 15.3.9.1. Company Overview
      • 15.3.9.2. Drug Class Portfolio
      • 15.3.9.3. SWOT Analysis
      • 15.3.9.4. Financial Overview
      • 15.3.9.5. Strategic Overview
    • 15.3.10. Johnson & Johnson
      • 15.3.10.1. Company Overview
      • 15.3.10.2. Drug Class Portfolio
      • 15.3.10.3. SWOT Analysis
      • 15.3.10.4. Financial Overview
      • 15.3.10.5. Strategic Overview